Anti-cancer

Olaparib

CAS No. 763113-22-0

A PARP inhibitor used in oral oncology formulations for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.

Olaparib is a targeted PARP-inhibitor oncology API manufactured by NovaAcura Biotech under GMP-compliant conditions. Full batch documentation and regulatory support are available for global oncology formulation partners.

Applications & Uses

A PARP inhibitor used in oral oncology formulations for BRCA-mutated ovarian, breast, pancreatic, and prostate cancers.

Full technical documentation, batch specifications and regulatory support (DMF/CEP) are available on request.

Need This Molecule at Scale?

Get in touch for pricing, lead times and full regulatory documentation.

Get In Touch